Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PI4KB | Q9UBF8 | 6/20 | 0.67 |
| ▸ | PIK3CG | P48736 | 10/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.59 |
| ▸ | MAPT | P10636 | 2/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.59 |
| ▸ | HPGD | P15428 | 1/20 | 0.59 |
| ▸ | HTT | P42858 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13135887 | 0.83 | PIK3CG (0.57) | PI4KBPIK3CGALDH1A1MAPTKDM4E | |
| SCHEMBL5960356 | 0.82 | PIK3CG (0.59) | PI4KBPIK3CGALDH1A1MAPTKDM4E | |
| SCHEMBL4528106 | 0.81 | PI4KB (1.00) | PI4KBPIK3CGALDH1A1MAPTKDM4E | |
| SCHEMBL4512892 | 0.80 | PIK3CG (1.00) | PI4KBPIK3CGALDH1A1MAPTKDM4E | |
| SCHEMBL4530751 | 0.80 | MAPT (0.81) | PI4KBPIK3CGALDH1A1MAPTKDM4E | |
| SCHEMBL4507830 | 0.79 | PI4KB (0.87) | PI4KBPIK3CGALDH1A1MAPTKDM4E | |
| SCHEMBL4513836 | 0.79 | PIK3CG (0.81) | PI4KBPIK3CGALDH1A1MAPTKDM4E | |
| SCHEMBL4523621 | 0.79 | PI4KB (0.71) | PI4KBPIK3CGALDH1A1MAPTKDM4E | |
| SCHEMBL4521807 | 0.78 | PIK3CG (0.73) | PI4KBPIK3CGALDH1A1MAPTKDM4E | |
| SCHEMBL5427675 | 0.78 | PIK3CG (1.00) | PI4KBPIK3CGALDH1A1MAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8802861-B2 | Thiazole derivatives and use thereof | MERCK SERONO SA (CH) | 2014-08-12 | — | — | US | claimed |
| US-20090029998-A1 | Thiazole Derivatives and Use Thereof | APPLIED RESEARCH SYSTEM ARS HOLDING N.V. (NL) | 2009-01-29 | — | — | US | claimed |
| EP-1709019-B1 | THIAZOLE DERIVATIVES AND USE THEREOF | APPLIED RESEARCH SYSTEMS (AN) | 2007-08-08 | — | — | EP | claimed |
| JP-2007517835-A | — | — | 2007-07-05 | — | — | JP | claimed |
| EP-1709019-A2 | THIAZOLE DERIVATIVES AND USE THEREOF | Applied Research Systems ARS Holding N.V. (AN) | 2006-10-11 | — | — | EP | claimed |
| WO-2005068444-A2 | THIAZOLE DERIVATIVES AND USE THEREOF | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2005-07-28 | — | — | WO | claimed |
| US-9150561-B2 | Thiazole derivatives and use thereof | MERCK SERONO S.A. (CH) | 2015-10-06 | — | — | US | disclosed |
| US-20140228365-A1 | THIAZOLE DERIVATIVES AND USE THEREOF | MERCK SERONO S.A. (CH) | 2014-08-14 | — | — | US | disclosed |
| US-8802861-B2 | Thiazole derivatives and use thereof | MERCK SERONO SA (CH) | 2014-08-12 | — | — | US | disclosed |
| US-20090029998-A1 | Thiazole Derivatives and Use Thereof | APPLIED RESEARCH SYSTEM ARS HOLDING N.V. (NL) | 2009-01-29 | — | — | US | disclosed |
| EP-1709019-B1 | THIAZOLE DERIVATIVES AND USE THEREOF | APPLIED RESEARCH SYSTEMS (AN) | 2007-08-08 | — | — | EP | disclosed |
| EP-1709019-A2 | THIAZOLE DERIVATIVES AND USE THEREOF | Applied Research Systems ARS Holding N.V. (AN) | 2006-10-11 | — | — | EP | disclosed |
| WO-2005068444-A2 | THIAZOLE DERIVATIVES AND USE THEREOF | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2005-07-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140228365-A1 | THIAZOLE DERIVATIVES AND USE THEREOF | PF4, TEC, PDGFRB | PI4KB 2458/4885PIK3CG 2806/4885ALDH1A1 234/4885 |
| US-20090029998-A1 | Thiazole Derivatives and Use Thereof | PDGFRB, PDGFRA, TEC | PI4KB 1755/4885PIK3CG 2526/4885ALDH1A1 174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.